Cancer Hospital of Shandong First Medical University
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours | Fibroblast Activation Protein (FAP)-Positive Advanced Solid Tumours | Recruiting | Early phase 1 | 2026-09-14 | NCT07808177 | |
| Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, cancer, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder | Recruiting | Phase 1 / Phase 2 | 2025-02-11 | NCT06819215 | |
| A Phase 2 Clinical Study of ABSK061 and ABSK043 | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 2 | 2024-11-19 | NCT06632262 |